Express Pharma
JUNE 19, 2025
Indian pharmaceutical companies supply more than 60 per cent of global demand for vaccines and over 40 per cent of generic medicines consumed in the United States (2). This includes risk-based identification of contamination vectors, proactive mitigation controls, and lifecycle review of effectiveness.
Putting Patients First Blog
MAY 6, 2025
33 These partnerships provide American patients with access to a wide range of critical medicines manufactured to rigorous quality standardsmedicines that complement, rather than compete with, domestic production. 2 (2022): e314e322. Journal of Oncology Practice 18, no. 6 Avalere Health, Majority of API in U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MARCH 12, 2025
The FDA has an established office in India overseeing the number of qualified manufacturers supplying generic medicines to the US. It has also introduced the Foreign Unannounced Inspection Pilot programme, conducting multiple unannounced and short-term notice inspections in India since March 2022.
pharmaphorum
OCTOBER 11, 2022
The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast. Indeed, of the 281 WHO-listed essential medicines, 100% of respiratory treatments are Teva’s. NB: Part 2 of ’Reuters Pharma 2022 – a day one overview’ will follow shortly….
Pharmaceutical Technology
DECEMBER 15, 2022
On November 16, 2022, Medicines for Europe (MFE), the generics and biosimilars body, called for EU and national reforms to improve the security of medicine supplies, including tackling the impact of inflation on the security of essential medicine supplies with smart procurement guidelines for medicine.
European Pharmaceutical Review
MARCH 14, 2023
In the judgment ‘Pharmacia & Upjohn SA vs Paranova A/S’ (CJEU judgment of 12 October 1999 in case C-379/97) 2 CJEU decided that BMS conditions apply also to the medicinal product rebranding. Four recent rulings on parallel imports In November 2022, the CJEU announced four rulings on the parallel import of medicinal products.
pharmaphorum
MARCH 14, 2022
For Sandoz, the acquisition gives it a technology platform in an area of the generic medicines market with a relatively high barrier to entry, as developing inhaled medicines poses “comparatively high technical complexity,” according to Sandoz chief executive Richard Saynor.
Expert insights. Personalized for you.
104 
Let's personalize your content